Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Isosorbide mononitrate
Martindale Pharmaceuticals Ltd
C01DA14
Isosorbide mononitrate
60mg
Modified-release capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02060100; GTIN: 5028613000441
D50205-A PACKAGE LEAFLET: INFORMATION FOR THE USER NYZAMAC ® SR 40 MG & 60 MG CAPSULES Isosorbide mononitrate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Please keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed on this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Nyzamac SR Capsules are and what they are used for. 2. What you need to know before you take Nyzamac SR Capsules. 3. How to take Nyzamac SR Capsules. 4. Possible side effects. 5. How to store Nyzamac SR Capsules. 6. Contents of the pack and other information. 1. WHAT NYZAMAC SR CAPSULES ARE AND WHAT THEY ARE USED FOR The name of your medicine is Nyzamac SR Capsules. The active ingredient is isosorbide mononitrate. Nyzamac SR Capsules belong to a group of medicines called nitrates. They are called prolonged-release capsules because they are manufactured in a way that allows the isosorbide mononitrate to be released and slowly absorbed by your body over a period of several hours. Nyzamac SR Capsules are used in adults to prevent angina (chest pain) and work by opening up blood vessels and reducing the pain. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE NYZAMAC SR CAPSULES DO NOT TAKE NYZAMAC SR CAPSULES IF YOU: • are under 18 years of age; • are allergic to isosorbide mononitrate or any other medicines known as nitrates (glyceryl trinitrate, isosorbide dinitrate), or any of the other ingredients of Nyzamac SR Capsules listed in section 6 (allergic reactions include mild symptoms such as itching and/or rash. More severe symptoms include swelling of the face, lips, tongue and/or throat with difficulty in swallowing or breathing); • have any i Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nyzamac SR 60mg Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 60 mg prolonged-release capsule contains 60 mg of isosorbide mononitrate. Excipients with known effect: Each 60mg capsule contains: Lactose (180mg/capsule) Sucrose (57.75 mg/capsule) For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Prolonged-release capsules, hard. The 60mg capsule is a size 1 capsule and has an opaque white cap printed with “ISMN SR” in black ink and an opaque white body printed with « 60 » in black ink, containing off-white to yellowish microgranules. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Nyzamac SR capsules are indicated in adults for the prophylactic treatment of angina pectoris. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults: One capsule once daily given in the morning. The dose may be increased up to 120 mg. The product must not be given in divided doses as a daily nitrate free period is required in order to prevent the development of tolerance. Thus, if more than one capsule is needed they must be taken simultaneously. The dose can be titrated to minimise the possibility of headache by initiating treatment by a lower dose for the first two to four days. Paediatric population The safety and efficacy of Nyzamac SR Capsules in children have not been established. Elderly: There is no evidence of a need for routine dose adjustment in the elderly, but care may be needed in those patients with increased susceptibility to hypotension, and in those with marked hepatic or renal insufficiency. The lowest effective dose should be used. There is a risk of tolerance developing to prolonged-release preparations. In such patients, intermittent therapy may be more appropriate (see section 4.4). As with other drugs for the treatment of angina pectoris, abrupt discontinuation of therapy may lead to exacerbation of symptoms. When discontinuing long-term treatment, the dosage should be reduced gradually over several days Read the complete document